These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20497745)

  • 61. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
    Yang SH; Choi JS; Choi DH
    Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans.
    Blech S; Ludwig-Schwellinger E; Gräfe-Mody EU; Withopf B; Wagner K
    Drug Metab Dispos; 2010 Apr; 38(4):667-78. PubMed ID: 20086031
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Irbesartan does not affect the pharmacokinetics of simvastatin in healthy subjects.
    Marino MR; Vachharajani NN; Hadjilambris OW
    J Clin Pharmacol; 2000 Aug; 40(8):875-9. PubMed ID: 10934672
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension.
    Watanabe H; Kosuge K; Nishio S; Yamada H; Uchida S; Satoh H; Hayashi H; Ishizaki T; Ohashi K
    Life Sci; 2004 Dec; 76(3):281-92. PubMed ID: 15531380
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1561-76. PubMed ID: 22022857
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of Silymarin on the In Vivo Pharmacokinetics of Simvastatin and Its Active Metabolite in Rats.
    Li Y; Wu Y; Li YJ; Meng L; Ding CY; Dong ZJ
    Molecules; 2019 Apr; 24(9):. PubMed ID: 31035343
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Role of esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on pharmacokinetic profiles of simvastatin and its active metabolite in rat.
    Li Z; Zhang J; Zhang Y; Zuo Z
    J Pharm Biomed Anal; 2019 May; 168():13-22. PubMed ID: 30776567
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Probable linagliptin-induced liver toxicity: a case report.
    Kutoh E
    Diabetes Metab; 2014 Feb; 40(1):82-84. PubMed ID: 24378344
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist.
    Gehin M; Sidharta PN; Gnerre C; Treiber A; Halabi A; Dingemanse J
    Eur J Clin Pharmacol; 2015 Jan; 71(1):15-23. PubMed ID: 25323804
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Analysis of secondary care data to evaluate the clinical relevance of the drug-drug interaction between amlodipine and simvastatin.
    Fuhrmann S; Koppen A; Seeling A; Knoth H; Schröder J
    Z Evid Fortbild Qual Gesundhwes; 2019 Oct; 146():21-27. PubMed ID: 31324418
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacokinetics of orally administered simvastatin in turkeys.
    Jasiecka A; Grabowski T; Maślanka T; Ziółkowski H; Jaroszewski JJ
    Pol J Vet Sci; 2013; 16(2):377-9. PubMed ID: 23971207
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin.
    Park CG; Lee H; Choi JW; Lee SJ; Kim SH; Lim HE
    Int J Clin Pharmacol Ther; 2010 Aug; 48(8):497-503. PubMed ID: 20650039
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Baicalein inhibits the pharmacokinetics of simvastatin in rats
    Meng M; Li X; Zhang X; Sun B
    Pharm Biol; 2021 Dec; 59(1):880-883. PubMed ID: 34214011
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects.
    Kim JR; Jung JA; Kim S; Huh W; Ghim JL; Shin JG; Ko JW
    Biomed Res Int; 2019; 2019():1365180. PubMed ID: 30729119
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of vitamin D on bioavailability and lipid lowering efficacy of simvastatin.
    Al-Asmari AK; Ullah Z; Al-Sabaan F; Tariq M; Al-Eid A; Al-Omani SF
    Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):87-94. PubMed ID: 24740652
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Physiologically Based Pharmacokinetic Model of the DPP-4 Inhibitor Linagliptin to Describe its Nonlinear Pharmacokinetics in Humans.
    Sarashina A; Chiba K; Tatami S; Kato Y
    J Pharm Sci; 2020 Jul; 109(7):2336-2344. PubMed ID: 32283067
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of four traditional Chinese medicines on the pharmacokinetics of simvastatin.
    Zhao Q; Jiang J; Hu P
    Xenobiotica; 2015; 45(9):803-10. PubMed ID: 25801058
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A case of simvastatin-induced myopathy with SLCO1B1 genetic predisposition and co-ingestion of linagliptin and Stevia rebaudiana.
    Chan JCM; Ng MH; Wong RSM; Tomlinson B
    J Clin Pharm Ther; 2019 Jun; 44(3):381-383. PubMed ID: 30714173
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A pharmacokinetic drug-drug interaction model of simvastatin and clarithromycin in humans.
    Methaneethorn J; Chaiwong K; Pongpanich K; Sonsingh P; Lohitnavy M
    Annu Int Conf IEEE Eng Med Biol Soc; 2014; 2014():5703-6. PubMed ID: 25571290
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Assessment of potential interaction between simvastatin and clarithromycin in healthy adult male subjects.
    Kaleem Z; Khan JA; Mushtaq Z; Altaf S; Javed I
    Pak J Pharm Sci; 2018 May; 31(3):801-806. PubMed ID: 29716858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.